Is EINECS 251-322-5 Safe in Breastfeeding

I am a breastfeeding mother and i want to know if it is safe to use EINECS 251-322-5? Is EINECS 251-322-5 safe for nursing mother and child? Does EINECS 251-322-5 extracts into breast milk? Does EINECS 251-322-5 has any long term or short term side effects on infants? Can EINECS 251-322-5 influence milk supply or can EINECS 251-322-5 decrease milk supply in lactating mothers?

Excreted into breast milk in non-significant amount without harm effects observed among breastfed infants of mothers treated with EINECS 251-322-5. In addition, a low oral bioavailability renders concentration in the infant's plasma be nil or low. Be aware of false negative results that may be obtained from infants with bacterial cultures when the mother is on antibiotics and higher risk of acute diarrhea by alteration of normal gut flora. When used in eye drops, because of a low dose and topical application with minimal absorption in the serum, it is compatible while breastfeeding.

EINECS 251-322-5 is poorly excreted into breastmilk. Newborn infants apparently absorb small amounts of other aminoglycosides, but serum levels with typical three times per day dosages are far below those attained when treating newborn infections and systemic effects of EINECS 251-322-5 are unlikely. Older infants would be expected to absorb even less EINECS 251-322-5. Because there is little variability in the milk EINECS 251-322-5 levels during multiple daily dose regimens, timing breastfeeding with respect to the dose is of little or no benefit in reducing infant exposure. Data are not available with single daily dose regimens. Monitor the infant for possible effects on the gastrointestinal flora, such as diarrhea, candidiasis (e.g., thrush, diaper rash) or rarely, blood in the stool indicating possible antibiotic-associated colitis. Maternal use of an ear drop or eye drop that contains EINECS 251-322-5 presents little or no risk for the nursing infant [4]

An infant was breastfed (extent not stated) until the 4th month postpartum. At 2 months of age, his mother was given a 2-week course of EINECS 251-322-5 150 mg three times daily plus meropenem for a cystic fibrosis exacerbation. infant displayed no change in stool pattern during the maternal treatment and had normal renal function at 6 months of age.[4][5]